(Q57529900)

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Challenging the cholinergic hypothesis in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Economic evaluation of donepezil in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Pharmacokinetic rationale for the rivastigmine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Glutamate transporters as drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Beta-amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Amyloid beta protein enhances the clearance of extracellular L-glutamate by cultured rat cortical astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A synaptic model of memory: long-term potentiation in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

NICE vindicated in UK's High Court.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.15.2575